<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938483</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-0010</org_study_id>
    <nct_id>NCT00938483</nct_id>
  </id_info>
  <brief_title>Tolerability and Safety of An Infant Formula</brief_title>
  <official_title>A Multicenter, Single-blind, Randomized, Phase II Study of the Tolerability and Safety of NPS-202 in Infants With Clinically Diagnosed Cow's Milk Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Nutritionals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perrigo Nutritionals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate an extensively hydrolyzed formula in infants with
      cow's milk allergy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infant reactivity to an extensively hydrolyzed infant formula</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Milk Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Extensively hydrolyzed infant formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New extensively hydrolyzed formula, NPS-202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant formula - Extensively hydrolyzed Nutramigen Lipil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Currently marketed extensively hydrolyzed formula (Nutramigen Lipil)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nutramigen Lipil (Infant formula)</intervention_name>
    <arm_group_label>Extensively hydrolyzed infant formula</arm_group_label>
    <arm_group_label>Infant formula - Extensively hydrolyzed Nutramigen Lipil</arm_group_label>
    <other_name>Extensively hydrolyed infant formula (Nutramigen Lipil)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinically diagnosed CMA

          -  &lt;/= 12 weeks at time of study entry

          -  full-term infant

          -  must be willing to use provided formula as sole source of nutrition

          -  other than CMA, infant must be otherwise healthy

        Exclusion Criteria:

          -  underlying or confounding gastrointestinal abnormalities

          -  infants born from an addictive situation, HIV positive

          -  if parent/guardian is considered likely to be non-compliant with the protocol
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia M Barber, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Perrigo Nutritionals</affiliation>
  </overall_official>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2009</study_first_posted>
  <last_update_submitted>July 14, 2009</last_update_submitted>
  <last_update_submitted_qc>July 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Cynthia Barber, PhD, Vice President, Regulatory, Medical and Clinical Affairs</name_title>
    <organization>PBM Products, LLC</organization>
  </responsible_party>
  <keyword>infant formula</keyword>
  <keyword>cow's milk allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Milk Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

